Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Perry

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
The Journal of Infectious Diseases|November 6, 2012
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
JAMA Oncology|October 29, 2020
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical TrialTimothy F Cloughesy, Kevin Petrecca, Tobias Walbert, et al.
Neuro-Oncology|March 19, 2024
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trialPatrick Roth, Thierry Gorlia, Jaap C Reijneveld, et al.
Heart Rhythm|August 1, 2021
Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardiaDania Kallas, Thomas M Roston, Sonia Franciosi, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
The Lancet. Haematology|September 25, 2020
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysisHolger J Schünemann, Matthew Ventresca, Mark Crowther, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
The Journal of Infectious Diseases|November 6, 2012
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
JAMA Oncology|October 29, 2020
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical TrialTimothy F Cloughesy, Kevin Petrecca, Tobias Walbert, et al.
Neuro-Oncology|March 19, 2024
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trialPatrick Roth, Thierry Gorlia, Jaap C Reijneveld, et al.
Heart Rhythm|August 1, 2021
Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardiaDania Kallas, Thomas M Roston, Sonia Franciosi, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
The Lancet. Haematology|September 25, 2020
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysisHolger J Schünemann, Matthew Ventresca, Mark Crowther, et al.
Pageof 11